{
    "clinical_study": {
        "@rank": "4948", 
        "acronym": "DREAM", 
        "arm_group": [
            {
                "arm_group_label": "Arm \u2160", 
                "arm_group_type": "Experimental", 
                "description": "Decitabine Injection 20mg/m2/d*5d, IV> 1h, one cycles per 4 weeks."
            }, 
            {
                "arm_group_label": "Arm \u2161", 
                "arm_group_type": "Experimental", 
                "description": "Decitabine Injection 12mg/m2/d*8d, IV> 1h, one cycles per 4 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate of the safety and efficacy of decitabine treatment\n      of Myelodysplastic Syndrome."
        }, 
        "brief_title": "A Phase \u2163 Study of Decitabine in Myelodysplastic Syndrome", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelodysplastic Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Total subjects: 240, dose\u2160group of 120 patients, dose\u2161group of 120 patients. Subjects are\n      stratified randomize. If necessary, participants accepted best supportive therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age\u226518;\n\n          -  The diagnosis of MDS patients comply WHO2008 standards;\n\n          -  IPSS score\u22650.5;\n\n          -  WHO classification for patients RCUD, RARS and transfusion-dependent RCMD;\n\n          -  ECOG PS score: 0-2;\n\n          -  Expected survival\u22653 months;\n\n          -  Serum bilirubin\u22641.5*ULN, serum ALT and AST\u22642.5*ULN, serum Cr\u22641.5*ULN;\n\n          -  Subjects signed informed consent form in line with GCP requirements.\n\n        Exclusion Criteria:\n\n          -  Can not marrow biopsy;\n\n          -  Previously diagnosed AML;\n\n          -  Received azacitidine or decitabine treatment any time before;\n\n          -  Being diagnosed with other malignancies in the prior 12 months;\n\n          -  Pregnant or lactating women;\n\n          -  Failure to control systemic fungal, bacterial or viral infection;\n\n          -  Known or suspected allergy to decitabine;\n\n          -  Known human immunodeficiency virus (HIV) or hepatitis B or C classes of active viral\n             infection;\n\n          -  Have a history of neurological or psychiatric disorders, including epilepsy or\n             dementia;\n\n          -  CTCAE 3  or 4 degree peripheral neuropathy;\n\n          -  According to the investigator's judgment, there are concomitant diseases with a\n             serious safety hazard or affect the patients completed the study in patients;\n\n          -  Using other experimental drugs or participating in other clinical trials in the prior\n             one months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013102", 
            "org_study_id": "DREAM-201"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm \u2160", 
                "Arm \u2161"
            ], 
            "description": "Decitabine Injection 20mg/m2/d*5d, IV> 1h, one cycles per 4 weeks; Decitabine Injection 12mg/m2/d*8d, IV> 1h, one cycles per 4 weeks.", 
            "intervention_name": "Decitabine Injection", 
            "intervention_type": "Drug", 
            "other_name": "qingweike"
        }, 
        "intervention_browse": {
            "mesh_term": "Decitabine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "contact": {
                "last_name": "LIU HUI, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China", 
                    "state": "Tianjin", 
                    "zip": "300052"
                }, 
                "name": "Tianjin Medical University General Hospital"
            }, 
            "investigator": {
                "last_name": "Shao Zonghong, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Controlled, Multi-center Collaborative Phase \u2163 Study to Evaluate the Safety and Efficacy of Decitabine in Myelodysplastic Syndrome", 
        "overall_contact": {
            "last_name": "Liu Hui, MD", 
            "phone": "0086-022-60362636"
        }, 
        "overall_official": {
            "affiliation": "Tianjin Medical University General Hospital", 
            "last_name": "Shao Zonghong, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy evaluation: ORR The secondary efficacy evaluation: CR\uff0cmCR\uff0cPR\uff0cHI, PFS in one year, Cytogenetic response, transfusion requirements, et al.", 
            "measure": "The safety and efficacy of decitabine treatment of Myelodysplastic Syndrome.", 
            "safety_issue": "Yes", 
            "time_frame": "2-4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013102"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Cttq", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cttq", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}